Overview Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Status: Completed Trial end date: 2017-03-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy. Phase: Phase 2 Details Lead Sponsor: Vascular Pharmaceuticals, Inc.